title: FDA as a catalyst for translation.
authors.affiliation: Robert M. Califf is Deputy Commissioner for Medical Products and Tobacco at the U.S. Food and Drug Administration (FDA), U.S. Department of Health and Human Services, Silver Spring, MD 20993, USA.Stephen Ostroff is Acting Commissioner at FDA, U.S. Department of Health and Human Services, Silver Spring, MD 20993, USA. robert.califf@fda.hhs.gov.
authors.forename: Robert M
authors.initials: RM
authors.lastname: Califf
authors.affiliation: Robert M. Califf is Deputy Commissioner for Medical Products and Tobacco at the U.S. Food and Drug Administration (FDA), U.S. Department of Health and Human Services, Silver Spring, MD 20993, USA.Stephen Ostroff is Acting Commissioner at FDA, U.S. Department of Health and Human Services, Silver Spring, MD 20993, USA.
authors.forename: Stephen
authors.initials: S
authors.lastname: Ostroff
mesh_terms: D002986:Clinical Trials as Topic; D003657:Decision Making; D017277:Drug Approval; D006801:Humans; D061214:Patient Safety; D010641:Phenotype; D049490:Systems Biology; D057170:Translational Research, Biomedical / Q000639:trends*; D014481:United States; D014486:United States Food and Drug Administration / Q000458:organization & administration*